Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05560646 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
A Phase 2 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 354
- Enrollment target
NCT05560646 is a Phase 2 study that has completed, run by Organon and. The registered enrollment target is 354 participants.
The verdict
NCT05560646, a Phase 2 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 354 participants
- Enrollment target
Study Summary
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Interventions
- DRUG Placebo
- DRUG OG-6219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05560646
The ClinicalTrials.gov registry entry for NCT05560646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05560646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05560646 about?
NCT05560646 is a clinical study titled "A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain". The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
What is the current status of trial NCT05560646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2022-10-25. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT05560646?
The interventions under investigation include: Placebo (DRUG), OG-6219 (DRUG).
Who is sponsoring clinical trial NCT05560646?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.